Panobinostat potentiates the cytotoxic effects of ara-C and daunorubicin on acute myeloid leukemia cells through suppressing the DNA damage response

被引：0
作者：
Xie, Chengzhi [1 ]
Edwards, Holly [1 ]
Drenberg, Christina [2 ]
Baker, Sharyn D. [2 ]
Inaba, Hiroto [2 ]
Buck, Steven A. [3 ]
Taub, Jeffrey W. [3 ]
Ge, Yubin [1 ]
机构：
[1] Barbara Ann Karmanos Canc Inst, Detroit, MI USA
[2] St Jude Childrens Res Hosp, Memphis, TN 38105 USA
[3] Childrens Hosp Michigan, Detroit, MI 48201 USA
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
10.1158/1538-7445.AM2012-2739
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2739
引用
收藏
页数：2
相关论文
共 50 条
[41]   INTERRELATIONSHIP OF DRUG SENSITIVITY OF CLONOGENIC ACUTE MYELOBLASTIC-LEUKEMIA (AML) CELLS TO DAUNORUBICIN (DNR), ETOPOSIDE (VP), AND ARABINOSYLCYTOSINE (ARA-C) [J].
DOW, LW ;
SCHELL, MJ .
PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1987, 28 :191-191
[42]   A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression [J].
Al-Kali, Aref ;
Tibes, Raoul ;
Atherton, Pamela ;
Palmer, Jeanne ;
Alkhateeb, Hassan B. B. ;
Patnaik, Mrinal ;
Begna, Kebede ;
Gangat, Naseema ;
Hashmi, Shahrukh ;
He, Rong ;
Litzow, Mark .
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 (03) :472-480
[43]   COMBINED ANTILEUKEMIC ACTIVITY OF PIXY-321 AND ARA-C AGAINST HUMAN ACUTE MYELOID-LEUKEMIA CELLS [J].
TANG, C ;
HUANG, Y ;
PONNATHPUR, VS ;
RAY, S ;
MAHONEY, ME ;
BULLOCK, G ;
IBRADO, AM ;
BHALLA, K .
LEUKEMIA & LYMPHOMA, 1994, 15 (5-6) :445-451
[44]   The Hsa-Let-7a miRNA Enhances Ara-C Induced Apoptosis in Human Acute Myeloid Leukemia Cells [J].
Chen, Ye ;
Jacamo, Rodrigo ;
Konopleva, Marina ;
Garzon, Ramiro ;
Croce, Carlo M. ;
Andreeff, Michael .
BLOOD, 2012, 120 (21)
[45]   Discovery of a Novel Dihydroorotate Dehydrogenase Inhibitor That Induces Differentiation and Overcomes Ara-C Resistance of Acute Myeloid Leukemia Cells [J].
Kitazawa, Satoshi ;
Ishii, Yukiko ;
Makita-Suzuki, Keiko ;
Saito, Koichi ;
Takayanagi, Kensuke ;
Sugihara, Hiromi ;
Matsuda, Shun ;
Yamakawa, Takayuki ;
Tsutsui, Yasuhiro ;
Tanaka, Tadashi ;
Hatta, Tomohisa ;
Natsume, Tohru ;
Kondo, Toru ;
Ishikawa, Yuichi ;
Hagiwara, Shinji ;
Kiyoi, Hitoshi .
BLOOD, 2019, 134
[46]   Dose escalation of ara-C may improve response rates in a subgroup of chronic myeloid leukemia patients with poor response to interferon-α and low-dose ara-C [J].
Hilbe, W ;
Kühr, T ;
Apfelbeck, U ;
Fridrik, M ;
Seewann, H ;
Stöger, M ;
Linkesch, W ;
Pont, J ;
Baldinger, C ;
Hartner, E ;
Bernhart, M ;
Geissler, D ;
Krieger, O ;
Lang, A ;
Lin, W ;
Ludwig, H ;
Duba, C ;
Greil, R ;
Gastl, G ;
Thaler, J .
LEUKEMIA & LYMPHOMA, 2001, 42 (06) :1283-1288
[47]   Trimidox, an inhibitor of ribonucleotide reductase potentiates the effects of Ara-C in HL-60 human promyelocytic leukemia cells. [J].
Karl, D ;
Horvath, Z ;
Bauer, W ;
Höchtl, T ;
Fritzer-Szekeres, M ;
Salamon, A ;
Grusch, M ;
Krupitza, G ;
Jäger, W ;
Elford, HL ;
Szekeres, T .
CLINICAL CANCER RESEARCH, 2001, 7 (11) :3744S-3745S
[48]   Anti-CD33 mAb enhances the cytotoxic effect of cytosine arabinoside (Ara-C) and idarubicin (IDA) on acute myeloid leukemia (AML) cells through similarities in their signaling pathways. [J].
Balaian, L ;
Ball, ED .
BLOOD, 2003, 102 (11) :871A-872A
[49]   Autophagy induction of Acute Myeloid Leukemia (AML) cells after treatment with low dose-cytarabine (Ara-C) and enhanced cytocidal effect on AML cells by combined treatment with ara-c plus lenograstim [J].
Tang, Yongmin ;
Li, Lixia ;
Wang, Di ;
Shen, Hongqiang ;
Qian, Baiqin ;
Luo, Chunfang ;
Zhang, Haizhong .
BLOOD, 2007, 110 (11) :114B-114B
[50]   Mylotarg, liposomal daunorubicin, Ara-C and cyclosporine (MDAC) regimen in patients with relapsed/refractory acute myelogenous leukemia (AML) [J].
Apostolidou, E ;
Cortes, J ;
Tsimberidou, AM ;
Estey, E ;
Kantarjian, H ;
Giles, F .
BLOOD, 2002, 100 (11) :268B-268B
12345